Overview Fundamentals API Earnings EOD API Sample Code Pricing

Immunoprecise Antibodies Ltd (IPA NASDAQ) stock market data APIs

$0.56 0.02(3.7%) as of October 17, 2024
Price chart is built with Anychart

ImmunoPrecise Antibodies Ltd., a biotechnology company, leverages multi-omics modeling and artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; peptide production for subsequent antibody discovery campaign; B cell select platform, which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. In addition, it provides phage display, a custom immune library; CAR development, an adaptable antibody, which allows the inclusion of functional data early in the screening funnel; antibody sequencing; and assay development. Further, it offers a profiling toolset for antibody lead candidates; and in vitro analytical tools for the study of quality attributes. Additionally, it provides LucinaTech, an antibody humanization to identify framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; antibody chimerization for cloning and production of antibody domain; Eurofins preclinical services; hybrid service model designed to reduce time and risk with custom applications; breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts; and protein manufacturing services. The company is headquartered in Victoria, Canada.

Immunoprecise Antibodies Ltd Financial Data Overview

0.539
0.56
-
0.578
0.4607
0.4607-2.6
15 663 K
27 916 K
24 093 K
-0.11
0.245
Our easy-to-use no-coding solutions help you get the data effortlessly:

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'IPA',
Type: 'Common Stock',
Name: 'Immunoprecise Antibodies Ltd',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000CR68W7',
ISIN: 'CA45257F2008',
CUSIP: NULL,
CIK: '1715925',
EmployerIdNumber: NULL,
FiscalYearEnd: 'April',
IPODate: '2017-01-03',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Immunoprecise Antibodies Ltd Fundamental Data is available in our Financial Data APIs

  • Net Revenue 24 093 K
  • EBITDA -11 505 000
  • Earnings Per Share -0.76
  • Income Statements
  • Balance Sheets
  • Cash flows
Get sample
of Fundamental API Data

Get Immunoprecise Antibodies Ltd Earnings via APIs

  • Latest Release 2024-09-16
  • EPS/Forecast -0.08

Get Immunoprecise Antibodies Ltd End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
Do you have any questions?
support@eodhistoricaldata.com